Tracking a Silent Killer: New Biomarker Identified for Arrhythmogenic Cardiomyopathy (1 of 1) (image)
Caption
Tissue from a heart of a patient with arrhythmogenic cardiomyopathy. This material relates to a paper that appeared in the Feb. 12, 2020, issue of Science Translational Medicine, published by AAAS. The paper, by J.-P. Song at Fuwai Hospital in Beijing, China; and colleagues was titled, " Elevated plasma β-hydroxybutyrate predicts adverse outcomes and disease progression in patients with arrhythmogenic cardiomyopathy."
Credit
J.-P. Song et al., Science Translational Medicine (2020)
Usage Restrictions
Please cite the owner of the material when publishing. This material may be freely used by reporters as part of news coverage, with proper attribution. Non-reporters must contact Science for permission.
Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.